NASDAQ:IVVD Invivyd (IVVD) Stock Price, News & Analysis $0.76 -0.01 (-1.30%) Closing price 04:00 PM EasternExtended Trading$0.76 0.00 (0.00%) As of 04:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Invivyd Stock (NASDAQ:IVVD) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Invivyd alerts:Sign Up Key Stats Today's Range$0.75▼$0.7950-Day Range$0.68▼$0.9952-Week Range$0.35▼$2.74Volume437,119 shsAverage Volume4.55 million shsMarket Capitalization$91.17 millionP/E RatioN/ADividend YieldN/APrice Target$5.85Consensus RatingBuy Company Overview Invivyd (NASDAQ: IVVD) is a clinical‐stage biopharmaceutical company focused on developing and commercializing novel therapies for patients with immune and autoimmune disorders. The company’s lead program is a high‐concentration subcutaneous immunoglobulin product designed to address primary immunodeficiency (PID) by offering more convenient administration and potentially fewer infusion‐related reactions compared to existing intravenous and subcutaneous formulations. Invivyd’s research and development efforts encompass both product optimization to enhance patient experience and expansion of its portfolio into other immunological indications. Invivyd operates a GMP‐compliant manufacturing facility in New Jersey and maintains research laboratories in the greater Boston area to support its clinical and preclinical initiatives. The company’s production platform leverages advanced fractionation and purification technologies to deliver high‐purity immunoglobulin preparations at increased concentrations, enabling reduced infusion volumes and shorter administration times. Invivyd has also established strategic partnerships with contract manufacturing organizations in Europe to ensure global supply chain resilience and to facilitate potential future launches in international markets. Founded in 2018 by a team of industry veterans and scientific leaders, Invivyd has assembled a seasoned leadership group to guide its clinical development and regulatory strategy. Chief Executive Officer John Simard brings more than two decades of experience in specialty pharmaceuticals, while Chief Scientific Officer Dr. Emily Chen has led immunoglobulin research programs at multiple biotech firms. The company’s board includes experts in immunology, neurology and rare diseases, reflecting Invivyd’s ambition to broaden its pipeline into conditions such as chronic inflammatory demyelinating polyneuropathy and certain autoimmune neurologic disorders. With its headquarters in Cambridge, Massachusetts, and operations extending to the United States and Europe, Invivyd is positioning itself to meet the unmet needs of patients who require lifelong immunoglobulin replacement therapy. By focusing on patient‐centric product design and leveraging a robust manufacturing footprint, the company aims to deliver differentiated therapies that improve both clinical outcomes and quality of life for individuals living with immune deficiencies and related conditions.AI Generated. May Contain Errors. Read More Invivyd Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks64th Percentile Overall ScoreIVVD MarketRank™: Invivyd scored higher than 64% of companies evaluated by MarketBeat, and ranked 356th out of 917 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingInvivyd has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageInvivyd has only been the subject of 2 research reports in the past 90 days.Read more about Invivyd's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Invivyd are expected to grow in the coming year, from ($1.64) to $0.11 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Invivyd is -0.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Invivyd is -0.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInvivyd has a P/B Ratio of 1.36. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Invivyd's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted6.46% of the float of Invivyd has been sold short.Short Interest Ratio / Days to CoverInvivyd has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Invivyd has recently decreased by 20.90%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldInvivyd does not currently pay a dividend.Dividend GrowthInvivyd does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted6.46% of the float of Invivyd has been sold short.Short Interest Ratio / Days to CoverInvivyd has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Invivyd has recently decreased by 20.90%, indicating that investor sentiment is improving significantly. News and Social Media1.1 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 3 news articles for Invivyd this week, compared to 2 articles on an average week.Search Interest6 people have searched for IVVD on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat Follows1 people have added Invivyd to their MarketBeat watchlist in the last 30 days. Company Ownership3.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Invivyd insiders have not sold or bought any company stock.Percentage Held by Insiders25.40% of the stock of Invivyd is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions70.36% of the stock of Invivyd is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Invivyd's insider trading history. Receive IVVD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Invivyd and its competitors with MarketBeat's FREE daily newsletter. Email Address IVVD Stock News HeadlinesNational Comprehensive Cancer Network® (NCCN®) Guidelines Recommend Monoclonal Antibodies for COVID-19 Prevention in People with Cancer; New Data Published in JAMA Oncology Underscore Severe Impact of COVID-19 on This PopulationJuly 21 at 7:05 AM | globenewswire.comInvivyd (NASDAQ:IVVD) Trading 5.1% Higher - Here's WhyJuly 18, 2025 | americanbankingnews.comHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 trillion vault of untapped American wealth. Former CIA advisor Jim Rickards calls it the “Old Testament Wealth Code” — and says it could transform your financial future. He’s revealing everything in a new presentation.July 22 at 2:00 AM | Paradigm Press (Ad)Invivyd, Inc. (IVVD) stock price, news, quote & history - Yahoo FinanceJuly 8, 2025 | nz.finance.yahoo.comInvivyd and Leading Researchers Form SPEAR (Spike Protein Elimination and Recovery) Study Group to Assess the Effects of Monoclonal Antibody Therapy for Long COVID and COVID-19 Post-Vaccination SyndromeJuly 2, 2025 | globenewswire.comInvivyd, Inc. Announces Promising Phase 1/2 Data for VYD2311 Monoclonal Antibody Candidate in COVID-19 Prevention and TreatmentJune 26, 2025 | quiverquant.comQInvivyd Announces Positive Full Phase 1/2 Clinical Data for VYD2311, a Next Generation COVID-19 Monoclonal Antibody for Potential Use as a Non-Vaccine Preventative and for Treatment of Active InfectionJune 26, 2025 | globenewswire.comH.C. Wainwright Lowers Invivyd (IVVD) PT to $5 Amid Q1 2025 Revenue ShortfallMay 29, 2025 | msn.comSee More Headlines IVVD Stock Analysis - Frequently Asked Questions How have IVVD shares performed this year? Invivyd's stock was trading at $0.4431 on January 1st, 2025. Since then, IVVD stock has increased by 71.5% and is now trading at $0.76. How were Invivyd's earnings last quarter? Invivyd, Inc. (NASDAQ:IVVD) posted its earnings results on Thursday, May, 15th. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.04) by $0.10. The company had revenue of $11.30 million for the quarter, compared to the consensus estimate of $34.45 million. Invivyd had a negative net margin of 389.01% and a negative trailing twelve-month return on equity of 165.24%. Read the conference call transcript. How do I buy shares of Invivyd? Shares of IVVD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Invivyd own? Based on aggregate information from My MarketBeat watchlists, some other companies that Invivyd investors own include American Water Works (AWK), The RMR Group (RMR), Waste Connections (WCN), AU Optronics (AUOTY), DiamondRock Hospitality (DRH), Voyager Therapeutics (VYGR) and iShares Micro-Cap ETF (IWC). Company Calendar Last Earnings5/15/2025Today7/22/2025Next Earnings (Estimated)8/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IVVD CIK1832038 Webadagiotx.com Phone781-819-0080FaxN/AEmployees100Year FoundedN/APrice Target and Rating Average Price Target for Invivyd$5.85 High Price Target$9.00 Low Price Target$3.55 Potential Upside/Downside+665.7%Consensus RatingBuy Rating Score (0-4)3.25 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($1.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$169.93 million Net Margins-389.01% Pretax Margin-389.01% Return on Equity-165.24% Return on Assets-99.71% Debt Debt-to-Equity RatioN/A Current Ratio1.53 Quick Ratio1.53 Sales & Book Value Annual Sales$25.38 million Price / Sales3.61 Cash FlowN/A Price / Cash FlowN/A Book Value$0.56 per share Price / Book1.36Miscellaneous Outstanding Shares119,960,000Free Float89,491,000Market Cap$91.65 million OptionableOptionable Beta0.52 Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:IVVD) was last updated on 7/22/2025 by MarketBeat.com Staff From Our PartnersTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredBitcoin Beats Gold — But This Coin Could Beat Them BothBitcoin just hit a record high—but it’s not the top crypto play right now. Crypto analyst Juan Villaverde, ...Weiss Ratings | SponsoredTrump’s $100 Trillion Land Rush Is OnWhat Is "The US: IPO"? You won't hear this on CNBC... but the government may soon open up hundreds of trill...Stansberry Research | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredURGENT: Trump Could Buy 1,000,000 Bitcoins TOMORROW?According to one report, senior officials and crypto insiders recently discussed Bitcoin accumulation at the h...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Invivyd, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Invivyd With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.